Beatrice Borelli

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 315 citations · Full text

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

Oncology, Clinical Trials, Colorectal Cancer +9

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu et al. · The Oncologist · 2019 · 165 citations · Full text

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti, Sara Lonardi, Rossana Intini et al. · European Journal of Cancer · 2021 · 102 citations

Pan-immune-inflammation Value, Cancer Immunosurveillance, Medicine +12

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer

Roberto Moretto, Chiara Cremolini, Daniele Rossini et al. · The Oncologist · 2016 · 101 citations · Full text